HK Innoen Confirms Safety and Efficacy of Tecoprazan in Phase 3 Clinical Trial

[Asia Economy Reporter Minji Lee] HK inno.N announced on the 20th that it has demonstrated the non-inferiority of Tecoprazan compared to the comparator drug Lansoprazole in maintenance therapy after treatment of erosive gastroesophageal reflux disease, and confirmed its excellent tolerability.

The company stated, "We expect to provide patients who require maintenance therapy after treatment of erosive gastroesophageal reflux disease with a safe and effective treatment option over a long period," and added, "Based on the results of the Phase 3 clinical trial, we plan to apply for additional indications with the Ministry of Food and Drug Safety in Korea."

This content was produced with the assistance of AI translation services.